de Souza Dziedzom Komi, Owusu Irene Offei, Otchere Joseph, Adimazoya Michelle, Frempong Kwadwo, Ahorlu Collins Stephen, Boakye Daniel Adjei, Wilson Michael David
Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana.
Department of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana.
Pan Afr Med J. 2017 May 29;27:65. doi: 10.11604/pamj.2017.27.65.11004. eCollection 2017.
The development of antibody testing for the diagnosis of lymphatic filariasis (LF) is intended to enhance the monitoring and evaluation activities of the Global Program for the Elimination of LF. This is due to the fact that antibody tests are expected to be the most sensitive at detecting exposure to LF compared to antigen that takes longer to develop. To this end a new antibody-based enzyme linked immunosorbent assay (ELISA) to antigen Wb123 has been developed and further designed into a point of care rapid diagnostic test, under evaluation. In pre-treatment surveys, individuals were tested for antigen using the immuno-chromatographic test (ICT) card, and night blood microfilariae, after which all positives were treated using Ivermectin and Albendazole. The Wb123 ELISA was tested in antigen positive individuals, three months after they were treated. Samples were also tested for ICT and night blood microfilariae. The results revealed a reduction in microfilariae and ICT prevalence after treatment. Antigen and antibody prevalence increased with age. However, there was no correlation with the antibody responses observed. The mean WB123 antibody titers were higher among ICT positives, but not significantly different from ICT negative persons. While the Wb123 is targeted for use in untreated populations, further evaluations and guidelines will be required to define its use in populations that have undergone treatment for the control of LF.
开发用于诊断淋巴丝虫病（LF）的抗体检测方法旨在加强全球消除淋巴丝虫病规划的监测和评估活动。这是因为与需要更长时间才能产生的抗原相比，抗体检测在检测LF暴露方面预计最为敏感。为此，已经开发了一种针对抗原Wb123的基于抗体的新型酶联免疫吸附测定（ELISA），并进一步设计成一种即时检测快速诊断测试，正在进行评估。在治疗前调查中，使用免疫层析试验（ICT）卡检测个体的抗原以及夜血微丝蚴，之后所有阳性个体均使用伊维菌素和阿苯达唑进行治疗。在抗原阳性个体接受治疗三个月后，对其进行Wb123 ELISA检测。样本还进行了ICT和夜血微丝蚴检测。结果显示治疗后微丝蚴和ICT患病率降低。抗原和抗体患病率随年龄增加。然而，未观察到与抗体反应的相关性。ICT阳性个体的平均WB123抗体滴度较高，但与ICT阴性个体无显著差异。虽然Wb123的目标用途是未治疗人群，但需要进一步评估和制定指南来确定其在已接受LF治疗人群中的使用方法。
